Sputnik V becomes the world’s first COVID vaccine with proven efficacy for people living with HIV as demonstrated by a joint study between the Gamaleya Center and Moscow City Center for AIDS Prevention and Control published in The Lancet
Efficacy of Sputnik V is 79% against infection as confirmed by a retrospective cohort study analyzing data from more than 24,000 HIV+ patients on antiretroviral therapy (ART). The Gamaleya National Research Center of Epidemiology and Microbiology and the Russian Direct Investment Fund (RDIF), investor in Sputnik V and Sputnik Light vaccines, announced an article “Sputnik […]
Continue Reading